Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C

26.04.2008 19:00:07
Roche Pharmaceuticals: Basel, Switzerland (ots/PRNewswire) - - Roche Also Provides Comment on Results of"IDEAL" Trial Roche today announced that compelling new data from three studies indicate that chronic hepatitis C patients who received PEGASYS(R) ...

Lesen Sie hier weiter... | Drucken | PDF

Renewed Hope for a Cure: Extending Pegasys Treatment to 72 Weeks Provides New Treatment Option for Difficult-to-Treat Hepatitis C Patients
New Study Shows That Pegasys Regimen Provides Higher Cure Rates for Hepatitis C Patients
New Pegasys Data Show Hepatitis B Patients Achieve Highly Positive Treatment Response That Comes as Close to a Cure as Possible
European Commission Approval of New Indication for Roche's Pegasys(R) (peginterferon alfa-2a) Offers Hepatitis C Patients a Second Chance for a Cure
Aufruf der World Hepatitis Alliance an Regierungen, dringend Massnahmen gegen die chronische virale Hepatitis-B- und C-Epidemie zu ergreifen
Largest-Ever Studies on Most Common Form of Adult Leukemia, Show Patients Treated With MabThera Live Longer Without Disease Progressing
Tibotec Presents Interim Findings for TMC435, an Investigational Genotype 1 Hepatitis C Treatment, at the AASLD Liver Meeting 2008
Almirall and Forest Laboratories Announce Positive Results of Clinical Studies for Aclidinium Bromide, a Novel Long-Acting Anticholinergic for the Treatment for COPD
European Approval for Roche's Pegasys Personalises Treatment for a Subgroup of Hepatitis C Patients: Chance for Cure With Only Four Months of Treatment
Movetis Presents New Data at Digestive Disease Week

weitere Angebote: | Energie-Angebote - Strom-Angebote - Gas Angebote

Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C New Pegasys Data Show Hepatitis B Patients Achieve

2008 April 26 | Aktuelle News aus Deutschland und der Welt

Three Studies Presented at 43rd EASL Strongly Indicate Better.Efficacy for PEGASYS in Curing Hepatitis C.Basel, Switzerland (ots/PRNewswire)

Bankkaufmann - News

First-in-Class Hepatitis C Polymerase Inhibitor, Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing Hepatitis C

ots.at: das APA-OTS-Portal für multimediale Presseaussendungen

Three Studies Presented at 43rd EASL Strongly Indicate Better Efficacy for PEGASYS in Curing R1626, First-in-Class Hepatitis C Polymerase Inhibitor,